Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells

International Journal of Cancer

Volumn 137, Issue 4, 2015, Pages 978-990

  Hammer, Katharina ^a   Kazcorowski, Adam ^b   Liu, Li ^b   Behr, Michael ^a,c   Schemmer, Peter ^b   Herr, Ingrid ^b   Nettelbeck, Dirk M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Labor Dr von Froreich   (Germany)

Author keywords

carrier cells; oncolytic adenovirus; pancreatic cancer; prodrug activation; TRAIL

Indexed keywords

FLUCYTOSINE; FLUOROURACIL; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUSES;

ADENOVIRIDAE; ARTICLE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR SPHEROID; VIRUS CAPSID; VIRUS ENTRY; VIRUS GENE; VIRUS REPLICATION; CELL LINE, TUMOR; GENETIC VECTORS; GENETICS; HUMANS; INDIVIDUALIZED MEDICINE; MESENCHYMAL STROMAL CELLS; METABOLISM; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; INDIVIDUALIZED MEDICINE; MESENCHYMAL STROMAL CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931577261     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29442     Document Type: Article

References (59)

1. Russell SJ, Peng KW, Bell JC., Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-70.
2. Cattaneo R, Miest T, Shashkova EV, et al., Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-40.
3. Yamamoto M, Curiel DT., Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010; 18: 243-50.
4. Willmon C, Harrington K, Kottke T, et al., Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 2009; 17: 1667-76.
5. Hamada K, Desaki J, Nakagawa K, et al., Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther J Am Soc Gene Ther 2007; 15: 1121-8.
6. Reagan MR, Kaplan DL., Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells 2011; 29: 920-7.
7. Aggarwal S, Pittenger MF., Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22.
8. Dwyer RM, Kerin MJ., Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets? Hum Gene Ther 2010; 21: 1506-12.
9. Pereboeva L, Komarova S, Mikheeva G, et al., Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003; 21: 389-404.
10. Sonabend AM, Ulasov IV, Tyler MA, et al., Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008; 26: 831-41.
11. Stoff-Khalili MA, Rivera AA, Mathis JM, et al., Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007; 105: 157-67.
12. Komarova S, Kawakami Y, Stoff-Khalili MA, et al., Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755-66.
13. Xia X, Ji T, Chen P, et al., Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors. Mol Cancer 2011; 10: 134.
14. Dembinski JL, Spaeth EL, Fueyo J, et al., Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 2010; 17: 289-97.
15. Mader EK, Maeyama Y, Lin Y, et al., Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res Off J Am Assoc Cancer Res 2009; 15: 7246-55.
16. Garcia-Castro J, Alemany R, Cascallo M, et al., Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther 2010; 17: 476-83.
17. Conget PA, Minguell JJ., Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 2000; 28: 382-90.
18. Hakkarainen T, Sarkioja M, Lehenkari P, et al., Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 2007; 18: 627-41.
19. Mizuguchi H, Sasaki T, Kawabata K, et al., Fiber-modified adenovirus vectors mediate efficient gene transfer into undifferentiated and adipogenic-differentiated human mesenchymal stem cells. Biochem Biophys Res Commun 2005; 332: 1101-6.
20. Dmitriev I, Krasnykh V, Miller CR, et al., An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-13.
21. Krasnykh VN, Mikheeva GV, Douglas JT, et al., Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70: 6839-46.
22. Nokisalmi P, Pesonen S, Escutenaire S, et al., Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 2010; 16: 3035-43.
23. Kim KH, Dmitriev I, O'Malley JP, et al., A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 2012; 18: 3440-51.
24. Koski A, Kangasniemi L, Escutenaire S, et al., Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18: 1874-84.
25. Cody JJ, Douglas JT., Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009; 16: 473-88.
26. Rohmer S, Quirin C, Hesse A, et al., Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner. Virology 2009; 395: 243-54.
27. Cherubini G, Kallin C, Mozetic A, et al., The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther 2011; 18: 1157-65.
28. Oberg D, Yanover E, Adam V, et al., Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res 2010; 16: 541-53.
29. Stuckey DW, Shah K., TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 2013; 19: 685-94.
30. Ashkenazi A, Pai RC, Fong S, et al., Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investig 1999; 104: 155-62.
31. Walczak H, Miller RE, Ariail K, et al., Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
32. Griffith TS, Stokes B, Kucaba TA, et al., TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009; 9: 9-19.
33. Lavazza C, Carlo-Stella C, Giacomini A, et al., Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood 2010; 115: 2231-40.
34. Sova P, Ren XW, Ni S, et al,. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9: 496-509.
35. Jacob D, Davis J, Zhu H, et al., Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 2004; 10: 3535-41.
36. Katz MH, Spivack DE, Takimoto S, et al., Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol 2003; 10: 762-72.
37. Moniri MR, Sun XY, Rayat J, et al., TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther 2012; 19: 652-8.
38. Mueller LP, Luetzkendorf J, Widder M, et al., TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 2011; 18: 229-39.
39. Quirin C, Rohmer S, Fernandez-Ulibarri I, et al., Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy. Hum Gene Ther 2011; 22: 389-404.
40. Kaliberov SA, Chiz S, Kaliberova LN, et al., Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. Cancer Gene Ther 2006; 13: 203-14.
41. Kanyama H, Tomita N, Yamano T, et al., Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res 2001; 61: 14-8.
42. Wang XP, Yazawa K, Yang J, et al., Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. J Gastrointestinal Surg Off J Soc Surg Aliment Tract 2004; 8: 98-108; discussion 6-8.
43. Ruckert F, Aust D, Bohme I, et al., Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. J Surg Res 2012; 172: 29-39.
44. Fredebohm J, Boettcher M, Eisen C, et al., Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system. PloS One 2012; 7: e48503.
45. Apel A, Groth A, Schlesinger S, et al., Suitability of human mesenchymal stem cells for gene therapy depends on the expansion medium. Exp Cell Res 2009; 315: 498-507.
46. Erbs P, Regulier E, Kintz J, et al., In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-22.
47. Siegel G, Kluba T, Hermanutz-Klein U, et al., Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med 2013; 11: 146.
48. Mehta G, Hsiao AY, Ingram M, et al., Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Controlled Release 2012; 164: 192-204.
49. Sauthoff H, Heitner S, Rom WN, et al., Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 2000; 11: 379-88.
50. White E, Cipriani R, Sabbatini P, et al., Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J Virol 1991; 65: 2968-78.
51. Dong F, Wang L, Davis JJ, et al., Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 2006; 12: 5224-30.
52. Jimenez JA, Li X, Zhang YP, et al., Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Ther 2010; 17: 180-91.
53. Yong RL, Shinojima N, Fueyo J, et al., Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009; 69: 8932-40.
54. Schmitz M, Graf C, Gut T, et al., Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses. Gene Ther 2006; 13: 893-905.
55. Ibrahim SM, Ringel J, Schmidt C, et al., Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001; 23: 72-9.
56. Khanbolooki S, Nawrocki ST, Arumugam T, et al., Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006; 5: 2251-60.
57. Matsuzaki H, Schmied BM, Ulrich A, et al., Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res 2001; 7: 407-14.
58. Dimberg LY, Anderson CK, Camidge R, et al., On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013; 32: 1341-50.
59. Diallo JS, Roy D, Abdelbary H, et al., Ex vivo infection of live tissue with oncolytic viruses. J Vis Exp 2011; 52: 2854.